At-home Leqembi still requires clinic-based MRI monitoring for ARIA in 2026. People with mild cognitive impairment need baseline and follow-up brain scans, Medicare registry enrollment, and injection training even when shots happen at home.
ARIA means amyloid-related imaging abnormalities, swelling or bleeding in the brain seen on MRI. Eisai and Biogen announced on July 13, 2026 that FDA approved a 500-mg weekly subcutaneous initiation dose, given as two 250-mg autoinjector shots, which allows starting and continuing treatment at home the FDA approval notice. That option covers early Alzheimer's disease, not later dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can start treatment at home?
- What MRI schedule does the label require?
- How does Medicare coverage work?
- What clinic support still stays in place?
Who can start treatment at home?
Leqembi is for mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia with confirmed amyloid-beta pathology. Mild cognitive impairment means memory or thinking changes that are noticeable but do not prevent daily tasks. Amyloid confirmation usually requires PET scan or spinal-fluid testing ordered by a dementia specialist.
ApoE ε4 testing is needed before starting to assess ARIA risk. People with two copies of ApoE ε4 make up about 15% of Alzheimer's patients and had about 45% ARIA incidence on Leqembi. A higher-risk result does not always block treatment, but it changes counseling and vigilance.
What MRI schedule does the label require?
The FDA-approved label requires a recent baseline brain MRI plus follow-up MRIs after about 1, 2, 3, and 6 months, according to the current prescribing information the current prescribing information. Scans should generally occur within one week before the next dose and be reviewed before dosing. The same rule applies to IV and subcutaneous treatment.
FDA also recommended an earlier MRI before the third IV infusion to catch ARIA-E, or brain swelling and fluid, sooner. That added scan supplemented the prior schedule before the 5th, 7th, and 14th infusions. Missing or delaying a scan means delaying the dose until the result is checked.
How does Medicare coverage work?
Medicare covers Leqembi only under National Coverage Determination 200.3 through Coverage with Evidence Development. CMS requires mild cognitive impairment or mild dementia, amyloid confirmation, and enrollment of both physician and patient in a CMS-approved registry with follow-up data the Medicare coverage determination.
In practice, coverage depends on finding a registry site and completing required visits and reports. A prescription alone does not create coverage. Families should confirm registry enrollment, scan scheduling, and follow-up reporting before planning home dosing.
What clinic support still stays in place?
Home shots do not remove clinic work. MRI surveillance, injection training, and clinician oversight for symptoms remain required for both routes. Patients and care partners must learn storage, injection technique, dose timing, and when to call for headache, confusion, dizziness, vision change, or weakness.
Useful questions for the prescribing clinic include: The initiation autoinjector was planned for U.S. distribution in late August 2026 through specialty pharmacy. Access remains limited where MRI capacity, registry sites, or training support are unavailable, so arrange those three before bringing the first doses home.
- Where will baseline and month 1, 2, 3, and 6 MRIs be scheduled and read?
- Who provides autoinjector training and a backup plan for missed or partial doses?
- How are ARIA symptoms triaged nights and weekends?
